Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code Data collection
Data analysis
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub Fig. 7 and Supplementary Figs. S1-10 is provided as Source Data file. All the other data supporting the findings of this study are available within the article and its supplementary information files and from the corresponding author upon reasonable request.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size

Data exclusions
Replication Randomization
Blinding
Behavioural & social sciences study design All studies must disclose on these points even when the disclosure is negative. All studies must disclose on these points even when the disclosure is negative.
Study description
The sample size was determined according to previous literatures in the same research area for statistical power.
No data were excluded from our analyses.
All the experimental findings were reliably reproduced. The replication is indicated in corresponding Figure legends.
Mice were randomly and equally allocated into control and treated groups. Tumor specimens harvested from primary tumors of patients who underwent surgical resection at the Department of Musculoskeletal Oncology, First Affiliated Hospital, Sun Yat-sen University, between 2014 and 2017. All samples were collected without bias.
The investigators were blinded to group allocation during collection and/or analysis.
Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).
State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.
Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.
Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.
Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.
If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation. Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.
Describe the data collection procedure, including who recorded the data and how.
Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.
Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.
Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.
Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).
State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).
Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).
Describe any disturbance caused by the study and how it was minimized. 
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals
Wild animals
Field-collected samples
Ethics oversight
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants
Policy information about studies involving human research participants
Population characteristics
Recruitment
Ethics oversight
The validation and application of primary antibody were in online databases. The information of antibody p-T437(CBX4) was in Supplementary Table 5 . The species of Flag, Myc, HA, V5, GAPDH, Tubulin, CBX4, Runx2, Ck1!, GCN5, CHIP, H3K27ac, CBX4(IHC), "-catenin, p-T437 antibodies is Rabbit, the species of RNA polymerase II, HA-agrose beads, Flag-agrose beads, Myc-agrose beads is Mouse. The Flag, Myc, HA, V5, GAPDH, Tubulin, Runx2, "-catenin, p-T437 antibodies are used for western blot, the CBX4, Ck1!, CHIP, GCN5 antibodies are used for WB and IP, the CBX4, GCN5, H3K27Ac, RNA polymerase II are used for ChIP, the CBX4 (IHC) and CK1! are used for IHC, the Flag, HA, Myc agarose are used for IP.
The hFOB1.19, U2OS, MG63, 143B, HOS and HEK293T embryonic kidney cells were obtained from the American Type Culture Collection (ATCC) , The ZOS and ZOS-M, syngeneic human osteosarcoma cell lines derived from a primary tumor and metastasis, respectively, from the same patient, Starting with U2OS osteosarcoma cell line, the MTX300-resistant variant was obtained by exposing the parental line in vitro to stepwise the increased MTX concentrations.
Each cell line used were authenticated in Guangzhou Cellcook Biotech. 1. PCR is amplified with STR Multi-amplification Kit (PowerPlexTM16HS System); 2. PCR products are assayed with 3100 DNA Analyzer (Applied Biosystems®). 3. Amplification of gene COX1 and electrophoresis are employed to survey the species of the sample.
The cell lines we used in this manuscript were negative for mycoplasma
No
Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).
Indicate where the specimens have been deposited to permit free access by other researchers.
If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.
Male 4-6-week-old BALB/c nude mice were used for our experiments. Please see the Animal experiments section of Methods.
No Animal experiments were approved by the Animal Research Committee of Sun Yat-sen University Cancer Center and performed in accordance with established guidelines.
Please see the Supplementary Data.
Tumor specimens harvested from primary tumors of patients who underwent surgical resection at the Department of Musculoskeletal Oncology, First Affiliated Hospital, Sun Yat-sen University, between 2014 and 2017, were reviewed by a pathologist and immediately frozen and stored at $80°C until use. All samples were collected without bias.
The study design and use of clinical osteosarcoma fresh tissues and paraffin-embedded tissue samples were approved by the Institutional Review Board of Sun Yat-sen University.
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October 2018 Clinical data Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links
May remain private before publication.
Files in database submission
Genome browser session The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation
Instrument
Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.
Note where the full trial protocol can be accessed OR if not available, explain why.
Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.
Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.
For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.
Provide a list of all files available in the database submission.
Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.
Describe the experimental replicates, specifying number, type and replicate agreement.
Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired-or single-end.
Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.
Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.
Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.
To prepare the cells for flow cytometry sorting, live cells were harvested, resuspended in phosphate-buffered saline (PBS) with 10% fetal bovine serum and filtered using a 40 #m cell strainer (BD Falcon, Franklin Lakes, NJ, USA 
Correction
FlowJo (v10) The EGFP/DsRed ratio is able to reflect protein stability in cells, which indicated that cells with altered EGFP/DsRed ratios may be sorted by flow cytometry.
Using the FSC/SSC gating, debris was removed by gating on the main cell population. Isotype control stained cells were used to distinguish between background staining and specific antibody staining.
